By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Upsher-Smith Laboratories, Inc. 

14905 23rd Avenue North

Minneapolis  Minnesota  55447  U.S.A.
Phone: 800-328-3344 Fax:


Company News
Upsher-Smith Laboratories Announces Start Of First In Human Clinical Trial In Oncology With Novel CXCR4 Antagonist USL311 5/16/2016 7:25:38 AM
ANDROXY (Fluoxymesterone Tablets, USP) CIII Available Exclusively Through Upsher-Smith Laboratories 4/25/2016 7:28:00 AM
Upsher-Smith Laboratories Release: Research Presented At 68th Annual Meeting Of The American Academy of Neurology Estimates That More Than One Million U.S. Emergency Department Visits Annually Are Related To Epilepsy 4/18/2016 8:32:02 AM
Upsher-Smith Laboratories Recognizes Outstanding Achievements Of 43 U.S. Pharmacists 2/11/2016 10:01:57 AM
Upsher-Smith Laboratories And Sanion Sign Collaboration Agreement For Development Of Novel Therapeutics For Neurological Disorders 1/20/2016 7:36:22 AM
Upsher-Smith Laboratories Release: Seizure Clusters Significantly Impact Quality Of Life For Patients And Their Caregivers, According To A Landmark Survey Conducted By Harris Poll 12/7/2015 12:22:08 PM
Upsher-Smith Laboratories Presents Data Evaluating PK, PD And Tolerability Of Investigational Midazolam Nasal Spray In Healthy Geriatric And Non-Geriatric Adults 12/7/2015 7:55:58 AM
Roche (RHHBY), Upsher-Smith Laboratories Partner Up to Develop Inflammatory Disease Drug 12/1/2015 6:09:35 AM
Upsher-Smith Laboratories To Present New Data On Qudexy XR (topiramate) Extended-Release Capsules And USL261 (Investigational Intranasal Midazolam) 11/23/2015 7:28:48 AM
Upsher-Smith Laboratories Release: Data Published In Epilepsia Shows USL261 (Intranasal Midazolam) Demonstrated A Promising Pharmacokinetic Profile, Including Increased Relative Bioavailability, When Compared With Injectable Midazolam Administered Intranasally 11/9/2015 7:29:40 AM